A series of reviews focusing on the importance of learning from failed AlzheimerÂ’s disease clinical trials and a number of measures that may accelerate drug development against the disease.
Investigational drugs for the treatment of AD: what can we learn from negative trials?
Given the level of interest and activity in the race to find a treatment for Alzheimer's disease, it is expected that a reasonably safe and effective drug will be identified within the next decade. It may be w...